Wall Street sees huge upside after Novo Nordisk backs Veru
Veru (VERU) stock has not been easy to own.
The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster weight-loss medications.
But Veru just heard something rarely said to small biotechs: direct interest from one of the most powerful players in obesity medicine.
Novo Nordisk has agreed to provide Wegovy free of charge for Veru's Phase 2b PLATEAU trial, which is studying Veru's oral enobosarm in older persons with obesity who are taking Wegovy to lose weight. Veru will continue to be responsible for conducting and supporting the study.
And that alone means something.
The major detail is that Novo Nordisk also gained the right of first negotiation if Veru later opts to develop, sell, or license enobosarm alongside one of Novo Nordisk's GLP-1 medicines.
"The agreement evidences industry recognition of the need to improve upon existing weight-loss options," Oppenheimer analyst Leland Gershell said.
Veru believes it can solve a growing Wegovy problem
The GLP-1 boom has transformed health care.
Novo Nordisk's sales of obesity care increased by 26% in Danish kroner in 2025 to DKK 82.3 billion. The volume growth of the global branded GLP-1 obesity market reached 104%. Novo Nordisk reported its branded volume share of the market was 59.6%.
That growth goes some way to explaining why investors are intrigued with weight-loss medications.
Related: Morgan Stanley names UnitedHealth a "Top Pick"
But the next chapter of the obesity market may not be as simple as helping people lose more weight. It might be to assist them in losing weight better.
Reuters has revealed that many drugmakers are researching next-generation obesity drugs that aim to preserve muscle. This is an important problem as certain weight loss studies have indicated that a substantial part of weight loss might be from lean or fat-free mass, not just fat.
That's where Veru is looking to fit in.
Veru says enobosarm is an oral selective androgen receptor modulator intended to help make GLP-1 weight loss more selective to fat loss, while sparing lean mass and physical function.
The PLATEAU study looked at older persons with obesity, a population that may be particularly vulnerable to muscle loss with rapid weight loss.
That provides Veru a more specific pitch than just being another obesity-drug firm.
It tries to be a companion narrative for GLP-1.
That makes a difference. Veru doesn't have to beat Wegovy. It has to demonstrate that enobosarm can result in weight loss similar to Wegovy.
Wall Street thinks Veru stock could have massive upside
Oppenheimer maintained its outperform rating and $24 price target on Veru after the Novo Nordisk deal. That price target is significant, considering Veru traded recently around $3.40, giving it a market cap of roughly $54.6 million.
Novo Nordisk, however, was valued at over $189.6 billion on the previous market.
That enormous difference is why the Novo Nordisk deal is so important.
Even a little attention from a large pharma behemoth can alter the investment narrative for a micro-cap biotech.
More Health Care:
- If your Medicare plan was canceled, do this now
- Health care costs are the wild card in year-end tax planning
- 22 million Americans hit by ACA health insurance cliff after vote fails
But investors should be careful.
Novo Nordisk has not acquired Veru. It has not licensed enobosarm. It has not secured a commercial arrangement for the future.
Reports on the transaction also said Veru retains the global development and commercialization rights to its enobosarm.
Well, that's a good point.
If enobosarm works, Veru still has the asset. Novo Nordisk's risk is minimized if it fails.
Key takeaways for Veru investors
- Novo Nordisk will supply Wegovy for Veru's Phase 2b PLATEAU trial.
- Veru remains the trial sponsor and keeps control of enobosarm.
- Novo Nordisk received a right of first negotiation tied to future enobosarm combinations with Novo GLP-1 products.
- Oppenheimer kept an outperform rating and a $24 Veru price target.
- The central clinical question is muscle preservation during GLP-1 weight loss.
Veru still has to prove the science works
The bull case is easy to grasp.
The obesity market is huge. GLP-1 medicines are already blockbuster sellers. Drugmakers are seeking ways to improve outcomes, preserve muscle, and help patients stay on therapy longer.
If Veru's enobosarm can help patients lose weight on Wegovy and maintain lean mass, the company might be considerably more relevant.
But that remains an "if."
Veru is still a small biotech with clinical, regulatory, and finance risks. The company had a net loss of $2.7 million for the quarter and had $27.6 million in cash, cash equivalents, and restricted cash as of March 31, 2026.
That means the final decision on the Novo Nordisk deal will come down to trial data and whether it's a game-changer or just another biotech optimistic headline.
Investors have yet to be convinced. Small biotech businesses don't often get noticed by a pharmaceutical corporation worth nearly $200 billion for no reason.
Veru still has a long way to go to prove enobosarm can be a commercial success. But for now, Novo Nordisk has offered investors a reason to think Veru might be worth another look.
Related: Novo Nordisk partners with OpenAI to speed drug discovery
The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
This story was originally published June 7, 2026 at 4:03 PM.